Oramed Pharmaceuticals, Inc. (ORMP)
5.23
+0.02
(+0.38%)
USD |
NASDAQ |
Aug 26, 11:03
Oramed Pharmaceuticals Enterprise Value : 165.37M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 165.37M |
| August 24, 2026 | 149.26M |
| August 21, 2026 | 148.84M |
| August 20, 2026 | 148.02M |
| August 19, 2026 | 148.02M |
| August 18, 2026 | 147.60M |
| August 17, 2026 | 138.93M |
| August 14, 2026 | 135.21M |
| August 13, 2026 | 131.08M |
| August 12, 2026 | 126.53M |
| August 11, 2026 | 125.71M |
| August 10, 2026 | 123.64M |
| August 07, 2026 | 127.77M |
| August 06, 2026 | 127.77M |
| August 05, 2026 | 128.60M |
| August 04, 2026 | 134.38M |
| August 03, 2026 | 131.49M |
| July 31, 2026 | 118.27M |
| July 30, 2026 | 120.34M |
| July 29, 2026 | 114.14M |
| July 28, 2026 | 122.40M |
| July 27, 2026 | 121.99M |
| July 24, 2026 | 116.62M |
| July 23, 2026 | 121.99M |
| July 22, 2026 | 116.20M |
| Date | Value |
|---|---|
| July 21, 2026 | 116.20M |
| July 20, 2026 | 119.51M |
| July 17, 2026 | 116.62M |
| July 16, 2026 | 117.44M |
| July 15, 2026 | 117.86M |
| July 14, 2026 | 115.38M |
| July 13, 2026 | 113.52M |
| July 10, 2026 | 117.03M |
| July 09, 2026 | 122.81M |
| July 08, 2026 | 127.36M |
| July 07, 2026 | 127.77M |
| July 06, 2026 | 138.93M |
| July 02, 2026 | 140.17M |
| July 01, 2026 | 140.58M |
| June 30, 2026 | 148.84M |
| June 29, 2026 | 124.82M |
| June 26, 2026 | 126.05M |
| June 25, 2026 | 139.55M |
| June 24, 2026 | 110.90M |
| June 23, 2026 | 105.58M |
| June 22, 2026 | 99.03M |
| June 18, 2026 | 93.71M |
| June 17, 2026 | 90.03M |
| June 16, 2026 | 89.21M |
| June 15, 2026 | 92.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.207T |
| Pfizer Inc. | 214.62B |
| Yarrow Bioscience, Inc. | 3.306M |
| Liquidia Corp. | 6.179B |
| NRX Pharmaceuticals, Inc. | 132.95M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 78.16M |
| Total Expenses (Quarterly) | -78.16M |
| EPS Diluted (Quarterly) | 1.839 |
| Earnings Yield | 78.59% |
| Normalized Earnings Yield | 20.04 |